Predictive factors of poor response to therapy in Autoimmune Hepatitis

The prevalence of refractory Mycoplasma pneumoniae (MP) pneumonia is increasing. The present study aimed to identify the predictive factors of responses to treatment of MP pneumonia in children. A total of 149 children were diagnosed with MP pneumonia, of whom 56 were included in the good response group, 75 children in the slow response group, and 18 children in no response or progression group. Data on the clinical, laboratory, and radiologic features were retrospectively obtained through medical chart reviews. The severity of pneumonia, based on the extent of pneumonic lesions on chest x-ray (adjusted odds ratio (aOR), 10.573; 95% confidence intervals (CIs), 2.303−48.543), and lactate dehydrogenase (LDH) levels (aOR, 1.002; 95% CIs, 1.000–1.004) at the time of admission were associated with slow response to treatment of MP pneumonia. Pleural effusion (aOR, 5.127; 95% CIs, 1.404–18.727), respiratory virus co-infection (aOR, 4.354; 95% CIs, 1.374–13.800), and higher LDH levels (aOR, 1.005; 95% CIs, 1.002–1.007) as well as MP-specific IgM titer (aOR, 1.309; 95% CIs, 1.095–1.564) were associated with no response or progression of MP pneumonia. The area under the curve for the prediction of no or poor response in MP pneumonia using pleural effusion, respiratory virus co-infection, LDH levels, and MP-specific IgM titer at the time of admission was 0.8547. This study identified the predictive factors of responses to treatment of MP pneumonia in children, which would be helpful in establishing a therapeutic plan and predicting the clinical course of MP pneumonia in children.

Download Full-text

Philadelphia chromosome-positive adult acute leukemia with monosomy of chromosome number seven: A subgroup with poor response to therapy

Leukemia Research ◽

10.1016/0145-2126(83)90046-2 ◽

1983 ◽

Vol 7 (4) ◽

pp. 509-522 ◽

Cited By ~ 21

Author(s):

A.-M. Maddox ◽

M.J. Keating ◽

J. Trujillo ◽

A. Cork ◽

E. Youness ◽

...

Keyword(s):

Chromosome Number ◽

Acute Leukemia ◽

Philadelphia Chromosome ◽

Poor Response ◽

Response To Therapy ◽

Philadelphia Chromosome Positive

Download Full-text

Dysregulation of miR‐125b predicts poor response to therapy in pediatric acute lymphoblastic leukemia

Journal of Cellular Biochemistry ◽

10.1002/jcb.28017 ◽

2018 ◽

Vol 120 (5) ◽

pp. 7428-7438 ◽

Cited By ~ 2

Author(s):

Nashwa El‐Khazragy ◽

Amal Ali Elshimy ◽

Safaa Shawky Hassan ◽

Safa Matbouly ◽

Gehan Safwat ◽

...

Keyword(s):

Acute Lymphoblastic Leukemia ◽

Lymphoblastic Leukemia ◽

Poor Response ◽

Response To Therapy ◽

Pediatric Acute Lymphoblastic Leukemia

Download Full-text

Interaction Proteomics Identifies ERbeta Association with Chromatin Repressive Complexes to Inhibit Cholesterol Biosynthesis and Exert An Oncosuppressive Role in Triple-negative Breast Cancer

Molecular & Cellular Proteomics ◽

10.1074/mcp.ra119.001817 ◽

2019 ◽

Vol 19 (2) ◽

pp. 245-260 ◽

Cited By ~ 6

Author(s):

Elena Alexandrova ◽

Giorgio Giurato ◽

Pasquale Saggese ◽

Giovanni Pecoraro ◽

Jessica Lamberti ◽

...

Keyword(s):

Breast Cancer ◽

Gene Regulation ◽

Chromatin Remodeling ◽

Triple Negative Breast Cancer ◽

Triple Negative ◽

Cholesterol Biosynthesis ◽

Poor Response ◽

Response To Therapy ◽

Protein Partners ◽

Interaction Proteomics

Triple-negative breast cancer (TNBC) is characterized by poor response to therapy and low overall patient survival. Recently, Estrogen Receptor beta (ERβ) has been found to be expressed in a fraction of TNBCs where, because of its oncosuppressive actions on the genome, it represents a potential therapeutic target, provided a better understanding of its actions in these tumors becomes available. To this end, the cell lines Hs 578T, MDA-MB-468 and HCC1806, representing the claudin-low, basal-like 1 and 2 TNBC molecular subtypes respectively, were engineered to express ERβ under the control of a Tetracycline-inducible promoter and used to investigate the effects of this transcription factor on gene activity. The antiproliferative effects of ERβ in these cells were confirmed by multiple functional approaches, including transcriptome profiling and global mapping of receptor binding sites in the genome, that revealed direct negative regulation by ERβ of genes, encoding for key components of cellular pathways associated to TNBC aggressiveness representing novel therapeutic targets such as angiogenesis, invasion, metastasis and cholesterol biosynthesis. Supporting these results, interaction proteomics by immunoprecipitation coupled to nano LC-MS/MS mass spectrometry revealed ERβ association with several potential nuclear protein partners, including key components of regulatory complexes known to control chromatin remodeling, transcriptional and post-transcriptional gene regulation and RNA splicing. Among these, ERβ association with the Polycomb Repressor Complexes 1 and 2 (PRC1/2), known for their central role in gene regulation in cancer cells, was confirmed in all three TNBC subtypes investigated, suggesting its occurrence independently from the cellular context. These results demonstrate a significant impact of ERβ in TNBC genome activity mediated by its cooperation with regulatory multiprotein chromatin remodeling complexes, providing novel ground to devise new strategies for the treatment of these diseases based on ligands affecting the activity of this nuclear receptor or some of its protein partners.

Download Full-text

The Emerging Role of Microbiota and Microbiome in Pancreatic Ductal Adenocarcinoma

Biomedicines ◽

10.3390/biomedicines8120565 ◽

2020 ◽

Vol 8 (12) ◽

pp. 565

Author(s):

Sona Ciernikova ◽

Maria Novisedlakova ◽

Danka Cholujova ◽

Viola Stevurkova ◽

Michal Mego

Keyword(s):

Pancreatic Ductal Adenocarcinoma ◽

Malignant Tumors ◽

Current Knowledge ◽

Early Stage ◽

Poor Response ◽

Response To Therapy ◽

Oral Microbiome ◽

Ductal Adenocarcinoma ◽

The Impact

Pancreatic ductal adenocarcinoma (PDAC) is one of the most aggressive malignant tumors due to the absence of biomarkers for early-stage detection and poor response to therapy. Since mounting evidence supports the role of microbiota composition in tumorigenesis and cancer treatment, the link between microbiome and PDAC has been described. In this review, we summarize the current knowledge regarding the impact of the gut and oral microbiome on the risk of PDAC development. Microenvironment-driven therapy and immune system interactions are also discussed. More importantly, we provide an overview of the clinical trials evaluating the microbiota role in the risk, prognosis, and treatment of patients suffering from PDAC and solid tumors. According to the research findings, immune tolerance might result from the microbiota-derived remodeling of pancreatic tumor microenvironment. Thus, microbiome profiling and targeting represent the potential trend to enhance antitumor immunity and improve the efficacy of PDAC treatment.

Download Full-text

Identification of plasma microRNA-22 as a marker for the diagnosis, prognosis, and chemosensitivity prediction of osteosarcoma

Journal of International Medical Research ◽

10.1177/0300060520967818 ◽

2020 ◽

Vol 48 (12) ◽

pp. 030006052096781

Author(s):

Zhen-bin Diao ◽

Tian-xiao Sun ◽

Yi Zong ◽

Bo-chuan Lin ◽

Yuan-sheng Xia

Keyword(s):

Malignant Tumors ◽

Poor Response ◽

Response To Therapy ◽

Healthy Controls ◽

Significant Independent Predictor ◽

Large Tumor ◽

Altered Expression ◽

Reverse Transcription Pcr ◽

Noninvasive Biomarker ◽

Plasma Microrna

Objective MicroRNA (miR)-22 plays crucial roles in malignant tumors and is involved in regulation of chemosensitivity. Additionally, altered expression of circulating miR-22 has been reported in various cancers. This study was designed to investigate plasma miR-22 expression in patients with osteosarcoma (OS) and determine its diagnostic, prognostic, and chemosensitivity prediction value. Methods Plasma miR-22 levels in 120 patients with OS and 120 healthy controls were detected by real-time quantitative reverse transcription PCR. Associations of plasma miR-22 expression with the patients’ clinicopathological features and prognosis were then assessed. Results Plasma miR-22 levels in patients with OS were significantly lower than those in healthy controls. Low plasma miR-22 levels were correlated with large tumor size, advanced clinical stages, positive distant metastasis, and poor tumor response to preoperative chemotherapy. Plasma miR-22 could discriminate OS patients from controls and distinguish patients with a good response to therapy from those with a poor response to therapy. Multivariate analysis revealed that low plasma miR-22 expression was a significant independent predictor of unfavorable prognosis. Conclusions Altered plasma levels of miR-22 might serve as a novel, noninvasive biomarker for OS diagnosis, prognosis, and chemosensitivity prediction.

Download Full-text